[Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Prostatic neuroendocrine (NE) carcinoma is a rare disease with a poor prognosis because of its rapid progression and the androgen-independent characteristic, for which no successful therapy is available presently. We report a case of NE differentiated prostate cancer, which was diagnosed as adenocarcinoma initially and progressed with NE differentiation during the combined androgen blockade therapy.
Kitamoto
Koichiro
K
The Department of Urology, Osaka City University Graduate School of Medicine.
Hayashi
Teruaki
T
Tamada
Satoshi
S
Ezaki
Kazuyosi
K
Kawashima
Hidenori
H
Sugimura
Kazunobu
K
Nakatani
Tatsuya
T
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*
D000726:Androgen Antagonists